tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Cannara Biotech Upgrades to OTCQX and Sets Dates for Q1 Results and Shareholder Meeting

Story Highlights
  • Cannara Biotech has upgraded its U.S. trading venue to OTCQX, boosting visibility among American investors.
  • The company will report fiscal Q1 2026 results on January 26 and hold its virtual shareholder meeting on January 29.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Cannara Biotech Upgrades to OTCQX and Sets Dates for Q1 Results and Shareholder Meeting

Claim 50% Off TipRanks Premium

Cannara Biotech ( (TSE:LOVE) ) has provided an update.

Cannara Biotech has qualified to have its common shares traded on the OTCQX Best Market in the United States under the symbol LOVFF, upgrading from the OTCQB Venture Market while maintaining its listings on the TSX Venture Exchange and Frankfurt Stock Exchange. The move is expected to improve the company’s visibility and accessibility among U.S. investors, underscoring its adherence to higher financial reporting and governance standards and supporting its broader capital markets strategy. The company will release its fiscal first-quarter 2026 financial results on January 26, 2026, followed by an earnings webcast featuring management’s remarks and a Q&A session, and it also reminded shareholders of its virtual Annual General and Special Meeting scheduled for January 29, 2026, with proxy voting encouraged in advance.

The most recent analyst rating on (TSE:LOVE) stock is a Buy with a C$2.00 price target. To see the full list of analyst forecasts on Cannara Biotech stock, see the TSE:LOVE Stock Forecast page.

Spark’s Take on TSE:LOVE Stock

According to Spark, TipRanks’ AI Analyst, TSE:LOVE is a Outperform.

Cannara Biotech’s strong financial performance and positive corporate events are the most significant factors driving the score. Technical analysis and valuation are neutral, indicating a balanced outlook. The absence of earnings call data does not impact the overall score.

To see Spark’s full report on TSE:LOVE stock, click here.

More about Cannara Biotech

Cannara Biotech Inc. is a vertically integrated Canadian cannabis producer specializing in affordable, premium-grade cannabis and derivative products for the domestic market. Operating two mega facilities in Québec totaling over 1.65 million square feet and capable of producing up to 100,000 kg annually, the company leverages the province’s low electricity costs to support cost-efficient cultivation and strengthen its competitive positioning.

Average Trading Volume: 49,282

Technical Sentiment Signal: Buy

Current Market Cap: C$175.6M

For a thorough assessment of LOVE stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1